Clioquinol improves motor and non-motor deficits in MPTP-induced monkey model of Parkinson’s disease through AKT/mTOR pathway
This is a superb and detailed study of Clioquinol in a primate model of Parkinson’s disease and very much validates the iron toxicity theory of Parkinson’s and the ATH approach with Pbt434. Iron toxicity seems to be a key step in the aging process and if pbt434 shows efficacy there will be numerous age related conditions it may of benefit for.
Clioquinol (Pbt1) effective in primate Parkinson’s disease model
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(14.3%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $11.18K | 3.279M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 38 | 52064257 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 126697935 | 22 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| ATH (ASX) Chart |